■目前,程序性细胞死亡-1(PD-1)靶向治疗对相当少的患者无效,抗药性仍然无法克服。
■探讨免疫治疗的机制并确定肺腺癌(LUAD)的新治疗机会,使用单细胞RNA测序评估了对抗PD-1治疗有反应和无反应的患者的数据,并收集大量RNA测序。
■我们研究了在不同细胞类型中对免疫疗法有反应或无反应的基因表达,并揭示了单细胞水平的转录特征。为了最终探索抗PD-1治疗的分子反应或抗性,进行细胞-细胞相互作用以鉴定未治疗患者与未治疗患者之间不同的LRI(配体-受体相互作用)没有回应者,未经治疗的患者与响应者,和响应者与无回应者。接下来,基于73个LRI基因提出了两个分子亚群,1亚型的生存状态较差,可能是免疫抑制性肿瘤亚型。此外,基于LASSOCox回归分析结果,我们发现TNFSF13,AXL,KLRK1,FAS,PROS1和CDH1可以是不同的预后生物标志物,免疫浸润水平,以及对LUAD免疫疗法的反应。
■总之,免疫疗法的效果与LRIs评分有关,这表明针对这些LRI的潜在药物可能有助于免疫治疗的临床益处。我们的综合组学分析揭示了抗PD-1治疗反应的潜在机制,并为改善精确诊断和免疫治疗的潜在策略提供了丰富的线索。
UNASSIGNED: Currently, programmed cell death-1 (PD-1)-targeted treatment is ineffective for a sizable minority of patients, and drug resistance still cannot be overcome.
UNASSIGNED: To explore the mechanisms of immunotherapy and identify new therapeutic opportunities in lung adenocarcinoma (LUAD), data from patients who did and did not respond to the anti-PD-1 treatment were evaluated using single-cell RNA sequencing, and bulk RNA sequencing were collected.
UNASSIGNED: We investigated the gene expression that respond or not respond to immunotherapy in diverse cell types and revealed transcriptional characteristics at the single-cell level. To ultimately explore the molecular response or resistance to anti-PD-1 therapy, cell-cell interactions were carried out to identify the different LRIs (ligand-receptor interactions) between untreated patients vs. no-responders, untreated patients vs. responders, and responders vs. non-responders. Next, two molecular subgroups were proposed based on 73 LRI genes, and subtype 1 had a poor survival status and was likely to be the immunosuppressive tumor subtype. Furthermore, based on the LASSO Cox regression analysis results, we found that TNFSF13, AXL, KLRK1, FAS, PROS1, and CDH1 can be distinct prognostic biomarkers, immune infiltration levels, and responses to immunotherapy in LUAD.
UNASSIGNED: Altogether, the effects of immunotherapy were connected to LRIs scores, indicating that potential medications targeting these LRIs could contribute to the clinical benefit of immunotherapy. Our integrative omics analysis revealed the mechanisms underlying the anti-PD-1 therapy response and offered abundant clues for potential strategies to improve precise diagnosis and immunotherapy.